Retraction and republication for Lancet Resp Med tracheostomy paper

lancetrmA paper whose expression of concern we covered in November 2014 has been retracted and republished “because of the extent of the changes necessary,” according to the Lancet Respiratory Medicine.

This isn’t the first time we’ve seen retraction/republications at the Lancetaccompanied by thorough breakdowns of the problem.

This study was a meta-analysis of research on how the timing of tracheostomies — placing a breathing tube directly into the windpipe — affects patients’ mortality rate. The original paper found that critically ill patients who received a tracheostomy earlier fared better than those for whom the procedure was delayed for weeks after intubation, the recommended practice.

However, when the authors calculated how many patients died, they assumed that any patient who wasn’t discharged from the intensive care unit (ICU) had died there, instead of looking for other explanations. This made their estimates unreliable.

The publisher convened a panel, which ultimately decided retraction and republication was the most appropriate course of action.

The original expression of concern contained a quote from the authors about the “data discrepancy” that would later sink the paper: Continue reading Retraction and republication for Lancet Resp Med tracheostomy paper

You can’t make this stuff up: Plagiarism guideline paper retracted for…plagiarism

ijdermThis could be an April Fools’ joke. But it isn’t.

In what can only be described as an ironic twist, the Indian Journal of Dermatology is retracting a paper that presents guidelines on plagiarism for…wait for it…

Plagiarism.

Here’s the notice: Continue reading You can’t make this stuff up: Plagiarism guideline paper retracted for…plagiarism

Cancer Cell issues big correction over “incorrectly cropped” figures, other issues

cancer cell A 2014 Cancer Cell paper became the subject of an erratum in January 2015, shortly after PubPeer members began criticizing the data. However, many issues brought up by commenters weren’t addressed in the correction notice, including a figure that might be two experiments spliced together to look like one.

The paper, led by Guido Franzoso at Imperial College London, claims that a new cancer drug called DTP3 kills myeloma cells “without causing any toxic side effects,” according to a press release from the school. Guido Franzoso is the founder of Kesios Therapeutics, a drug company which is set to begin clinical trials on DTP3.

The correction indicates that Western blots were cropped badly, which omitted several panels discussed in the text, while an “extra time point” was included accidentally. An antibody was also omitted from the description of the procedure.

PubPeer commenters have noticed additional issues, such as a criticism of figure 3D, which were not included or changed in this correction.

Here’s the correction for “Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors”: Continue reading Cancer Cell issues big correction over “incorrectly cropped” figures, other issues

“Serious and obvious mistakes” kill paper on heart attacks in rats

j card pharmA group of researchers in China and the United States have retracted a 2014 paper in the Journal of Cardiovascular Pharmacology after discovering the data were fatally flawed.

The article examined whether the anti-arrhythmia drug zacopride affected cardiac remodeling after heart attack, and came from Bo-We Wu, of Shanxi Medical University, in Taiyuan, and colleagues, including one author from Savannah, Georgia.

Here’s more from the notice for “Activation of IK1 channel by zacopride attenuates left ventricular remodeling in rats with myocardial infarction”:

Continue reading “Serious and obvious mistakes” kill paper on heart attacks in rats

Drug paper gets a fix, notching several corrections

rsc_tb_1_3_COVER.inddThe Journal of Materials Chemistry B has issued a laundry list of corrections for a 2014 chemotherapy paper, which address re-use of “some text”, incorrectly stated doses, and miscalculations of the drug concentration, among other issues.

The paper described a new way to deliver gemcitabine via nanoparticles, focusing the drug on the tumors.

It turns out the authors’ focus wasn’t so clear when writing the paper. The researchers, at the Chinese Academy of Medical Science, Peking Union Medical College, and Tianjin University in China, said they used “some text” from two 2013 papers by a team of French oncologists “without appropriate attribution,” as well as repeatedly getting the in vivo dose wrong. The manuscript also contained several incorrect calculations of the “drug loading,” or the proportion of active drug.

Here’s the correction for “Tailor-made gemcitabine prodrug nanoparticles from well-defined drug–polymer amphiphiles prepared by controlled living radical polymerization for cancer chemotherapy” (free, but requires sign-in): Continue reading Drug paper gets a fix, notching several corrections

BioMed Central retracting 43 papers for fake peer review

bmc logoBioMed Central is retracting 43 papers, following their investigation into 50 papers that raised suspicions of fake peer review, possibly involving third-party companies selling the service.

In November 2014 we wrote about fake peer reviews for Nature; at that point there had been about 110 retractions across several journals. The addition of 16 retractions by Elsevier for the same reason, and today’s 43 from BMC, brings retractions resulting from the phenomenon up to about 170.

BMC has also contacted institutions regarding 60 additional papers that were rejected for publication, but seem to be part of the same kind of scam. Regarding the third-party agents, BMC senior editor of scientific integrity Elizabeth Moylan writes: Continue reading BioMed Central retracting 43 papers for fake peer review

Pain paper scratched for authorship issues

ejacoverA group of pain researchers in Austria has lost their 2014 paper in the European Journal of Anaesthesiology because one of the authors wasn’t, well, one of the authors.

The article, “Intravenous nonopioid analgesic drugs in chronic low back pain patients on chronic opioid treatment: A crossover, randomised, double-blinded, placebo-controlled study,” came from a team at the Medical University Vienna and Evangelical Hospital Vienna.

During the study, the authors tested whether intravenous infusions of nonopioid drugs (such as paracetamol, or Tylenol) helped people with chronic back pain who take opioids regularly. They found that people’s pain levels decreased in the days leading up to treatment, when they were receiving a placebo, but not after the actual infusion. The results likely stem from “expectation-related mechanisms,” they wrote. Continue reading Pain paper scratched for authorship issues

Two more retractions appear for prominent MIT cancer researcher Robert Weinberg

genes and developmentTwo identical retraction notices have popped up for MIT professor Robert Weinberg, a highly-cited cancer researcher who had a retraction and a correction in 2013, both in Cancer Cell. 

These two new retractions, in Genes and Development, stem directly from another paper by Weinberg and colleagues in Cell that will apparently be retracted, as the “same analytical methodology was used,” according to the notices [see bottom of the post for an update].

Weinberg is highly regarded, and at least 20 of his papers have been cited over a thousand times.

First author Scott Valastyan was a promising postdoc at the time of the paper’s publication. He was a 2011 Runyon Fellow at Harvard, a three-year, $156,000 award for outstanding cancer postdocs. He doesn’t seem to have published anything since 2012, though he is listed as a joint inventor with Weinberg on patents filed in 2009 and 2014.

Here are the notices for “Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis” (cited 73 times, according to Thomson Scientific’s Web of Knowledge) and “Activation of miR-31 function in already-established metastases elicits metastatic regression” (cited 54 times), both paywalled: Continue reading Two more retractions appear for prominent MIT cancer researcher Robert Weinberg

Sticky situation: Paper using honey for healing pulled over data issues

honey
Image via Hillary Stein

A paper on dressing wounds with honey has been retracted after the journal realized that an outlier patient was throwing off the data analysis.

Honey has been used for millennia as an antimicrobial wound dressing. Doctors can even buy sterile preparations of the sweetener. But the evidence that honey is better than other wound dressings is still inconclusive.

According to the retracted paper, published in International Wound Journal in 2008, Manuka honey has an acidic pH which helps reduce the alkaline environment of chronic woulds. Indeed, the authors found that Manuka honey dressings lowered wound pH and reduced wound size.

Sadly, the paper was pulled in 2014, after someone realized one patient had a particularly large wound that was throwing off statistics. The injury was 61 cm^2 at the beginning of the study, while the others ranged from .9 to 22 cm^2. After removing that patient from the analysis, the results no longer held up.

Continue reading Sticky situation: Paper using honey for healing pulled over data issues

Psychology retractions have quadrupled since 1989: study

stapel
Diederik Stapel

Marc Hauser. Dirk Smeesters. Diederik Stapel.

Psychology has been home to some of the most infamous cases of fraud in recent years, and while it’s just a few bad apples who are spoiling the bunch, the field itself has seen an overall increase in retractions, according to a new paper by Jürgen Margraf appearing in Psychologische Rundschau and titled “Zur Lage der Psychologie.”

That increase, Margraf found, is not entirely due to its most well-known fraudsters. Here’s the relevant figure:

Continue reading Psychology retractions have quadrupled since 1989: study